OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

The WOLVERINE meta-analysis reinforces the role of MDT in delaying disease progression in patients with oligometastatic ...